Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Sweden and internationally.
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Bonesupport Holding's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2B4 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 2B4 exceeded the German Biotechs industry which returned 3.7% over the past year.
Return vs Market: 2B4 exceeded the German Market which returned 6.1% over the past year.
Price Volatility Vs. Market
How volatile is Bonesupport Holding's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Bonesupport Holding undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 2B4 (€3.25) is trading below our estimate of fair value (€6.81)
Significantly Below Fair Value: 2B4 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 2B4 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 2B4 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2B4's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2B4 is overvalued based on its PB Ratio (11.5x) compared to the DE Biotechs industry average (3.2x).
How is Bonesupport Holding forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2B4 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2B4 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2B4 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2B4's revenue (44% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: 2B4's revenue (44% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2B4's Return on Equity is forecast to be high in 3 years time
How has Bonesupport Holding performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2B4 is currently unprofitable.
Growing Profit Margin: 2B4 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 2B4 is unprofitable, and losses have increased over the past 5 years at a rate of -20.4% per year.
Accelerating Growth: Unable to compare 2B4's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2B4 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 2B4 has a negative Return on Equity (-103.37%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Bonesupport Holding's financial position?
Financial Position Analysis
Short Term Liabilities: 2B4's short term assets (SEK207.3M) exceed its short term liabilities (SEK63.2M).
Long Term Liabilities: 2B4's short term assets (SEK207.3M) exceed its long term liabilities (SEK6.0M).
Debt to Equity History and Analysis
Debt Level: 2B4 is debt free.
Reducing Debt: 2B4 had no debt 5 years ago.
Inventory Level: 2B4 has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 2B4's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2B4 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 2B4 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Bonesupport Holding's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 2B4's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 2B4's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2B4's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2B4's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2B4's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Emil Billbäck (49yo)
Mr. Emil Billbäck has been Chief Executive Officer at BONESUPPORT HOLDING AB (publ) since March 01, 2018. Mr. Billbäck is the Chief Executive Officer of BONESUPPORT AB. He has over 20 years management expe ...
CEO Compensation Analysis
Compensation vs Market: Emil's total compensation ($USD589.01K) is about average for companies of similar size in the German market ($USD627.72K).
Compensation vs Earnings: Insufficient data to compare Emil's compensation with company performance.
|Chief Executive Officer||1.9yrs||kr5.73m||no data|
|Founder & Director||10.1yrs||kr217.00k||no data|
|Chief Financial Officer||1.3yrs||no data||no data|
|COO and Executive VP of Manufacturing & Supply||0yrs||no data||no data|
|Executive Vice President Global Marketing & Communications||0.9yrs||no data||no data|
|Head of Human Resources||2.3yrs||no data||no data|
|Executive Vice President of Quality Management & Regulatory Affairs||0.3yrs||no data||no data|
|Executive VP of R&D||2.8yrs||no data||no data|
|Executive Vice President of R&D||2.4yrs||no data||no data|
|GM & Executive VP Commercial Operations EUROW||0.3yrs||no data||no data|
Experienced Management: 2B4's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
|Founder & Director||10.1yrs||kr217.00k||no data|
|Chairman of the board||0.8yrs||kr304.00k||0.095% SEK165.5k|
Experienced Board: 2B4's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.
Bonesupport Holding AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Bonesupport Holding AB (publ)
- Ticker: 2B4
- Exchange: DB
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr1.833b
- Listing Market Cap: kr173.320m
- Shares outstanding: 52.36m
- Website: https://www.bonesupport.com
Number of Employees
- Bonesupport Holding AB (publ)
- Scheelevagen 19
- Skåne County
- 223 70
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BONEX||OM (OMX Nordic Exchange Stockholm)||Yes||Common Shares||SE||SEK||Jun 2017|
|0RQO||LSE (London Stock Exchange)||Yes||Common Shares||GB||SEK||Jun 2017|
|2B4||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jun 2017|
|BONEXS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||SEK||Jun 2017|
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Sweden and internationally. The company offers CERAMENT Bone Void Filler used to fill gaps and voids in bone; CERAMENT G, a gentamicin-eluting injectable synthetic bone substitute; and CERAMENT V, a vancomycin-eluting synthetic bone substitute. Its products are used in orthopedic markets. The company was founded in 1999 and is headquartered in Lund, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/25 22:59|
|End of Day Share Price||2020/02/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.